首页 > 文章详情

2024 SGO年会亮点揭晓：三项中国创新研究荣登LBA榜单

03月02日

编译：肿瘤资讯

来源：SGO官网

第55届2024年美国妇科肿瘤学会（SGO）年会将于2024年3月16日至18日在美国加利福尼亚州圣迭戈召开。备受瞩目的LBA（Late-Breaking Abstract）摘要名单已经揭晓。其中，三项来自中国的研究脱颖而出，成功入选LBA环节。

科学全体会议Ⅰ：最新科学发现和信息

Scientific Plenary I: News We Can All Use

专场时间：3月16日8:30 AM-9:45 AM（以下时间均为Central Time，比北京时间慢15个小时）

NRG GY018试验：帕博利珠单抗+卡铂/紫杉醇对比安慰剂+卡铂/紫杉醇治疗的子宫内膜癌患者，不同PD-L1状态下的总生存期和无进展生存期

Overall survival and progression-free survival by PD-L1 status in endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

讲者: Ramez N. Eskander, MD

Raludotatug deruxtecan单药治疗既往经治的卵巢癌患者：首次人体 I 期研究的亚组分析

Raludotatug deruxtecan monotherapy in patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human, phase I study

讲者: Kathleen N. Moore, MD

ENGOT-EN6-NSGO/GOG-3031/RUBY研究：接受 dostarlimab 联合化疗治疗的原发性晚期或复发性子宫内膜癌患者的总生存期

Overall survival in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6- NSGO/GOG-3031/RUBY

讲者: Matthew A. Powell, MD

innovaTV 301/ENGOT-cx12/GOG-3057：tisotumab vedotin与研究者选择的化疗2线或3线治疗复发性或转移性宫颈癌的疗效和安全性——一项全球、随机、开放标签、III期研究

Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global, randomized, open-label, phase III study

讲者: Brian M. Slomovitz, MD

ENGOT-EN6-NSGO/GOG-3031/RUBY研究：多塔利单抗联合化疗序贯多塔利单抗联合尼拉帕利维持治疗晚期复发性子宫内膜癌

Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy in patients with primary-advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

讲者：Mansoor R. Mirza, MD

科学全体会议Ⅱ：共同推动进步
Scientific Plenary II: Moving the Needle Together

专场时间：3月16日10:45 AM-12:00 PM

未经系统性盆腔淋巴结清扫术的 SLN 活检后早期宫颈癌患者的生存期：SENTIX前瞻性、单臂、国际试验 (CEEGOG CX-01；ENGOT-CX2) 的主要终点结局

Survival of patients with early-stage cervical cancer after SLN biopsy without systematic pelvic lymphadenectomy: Primary endpoint outcome of the SENTIX prospective, single-arm, international trial (CEEGOG CX-01; ENGOT-CX2)

讲者: David Cibula, MD

专题全体会议Ⅰ：推动目标的科学
Focused Plenary I: The Science to Drive Purpose

专场时间: 3月16日2:15 PM - 3:30 PM

在晚期或复发性子宫内膜样子宫内膜腺癌（ENPAC研究）中，基于恩杂鲁胺治疗反应的分子标志物

Molecular markers of response to enzalutamide-based therapy in advanced or recurrent endometrioid endometrial adenocarcinoma (ENPAC Study)

讲者: Anil K. Sood, MD

卵巢癌患者一线治疗后通过腹腔镜二次探查和循环肿瘤 DNA 检测微小残留病变的预后意义

Prognostic implications of minimal residual disease detection by second-look laparoscopy and circulating tumor DNA in patients with ovarian cancer after frontline therapy

讲者: Anne Knisely, MD

专题全体会议Ⅱ：Encore & More：宫颈癌前沿进展
Focused Plenary II: Encore & More: Cutting Edge Gyn Onc Care in Cervical Cancer

专场时间: 3月16日2:15 PM - 3:30 PM

GCIG INTERLACE试验：局部晚期宫颈癌诱导化疗后放化疗与单纯放化疗的随机、III期试验

A randomized, phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally-advanced cervical cancer: The GCIG INTERLACE Trial

讲者: Jonathan Ledermann, MD

BEATcc(ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030)：一线阿替利珠单抗联合贝伐珠单抗和含铂化疗治疗转移性（IVB期）、持续性或复发性宫颈癌的随机、III期试验

BEATcc (ENGOT-CX10/GEICO 68-C/JGOG1084/GOG-3030): A randomized, phase III trial of first-line atezolizumab with bevacizumab and platinumbased chemotherapy for metastatic (stage IVB), persistent, or recurrent cervical cancer

讲者: Ana Oaknin, MD, PhD

卡瑞利珠单抗联合famitinib对比卡瑞利珠单抗单药和研究者选择的化疗治疗复发性或转移性宫颈癌的总生存期结局

Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer

讲者: 吴小华, MD

科学全体会议Ⅳ：LBA摘要会议1
Scientific Plenary IV: Late Breaking Abstract Session 1

专场时间：3月17日4:15 PM - 5:30 PM

IA1 期 (LVSI +) 和 IA2-IB1 期 (GOG-278) 非根治性手术治疗（筋膜外子宫切除术或锥形切除术伴盆腔淋巴结清扫）前后的身体功能和生活质量评估

Evaluation of physical function and quality of life before and after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (GOG-278)

讲者: Allan L. Covens, MD, FRCSC

在NCI/NCORP 资助的IA1(LVSI +) 和 IA2-IB1(GOG-278) 期患者中评价非根治性手术治疗（筋膜外子宫切除术或锥形切除术联合盆腔淋巴结清扫术）后的疗效和生育力 (NCT01649089)

Evaluation efficacy and fertility after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (GOG-278) funded by NCI/NCORP (NCT01649089)

讲者: Allan L. Covens, MD, FRCSC

EZH2 抑制剂 tazemetostat 在伴和不伴 ARID1A 突变的晚期子宫内膜样子宫内膜癌和卵巢透明细胞癌患者中的临床活性 (NRG-GY014)

Clinical activity of tazemetostat, an EZH2 inhibitor, in patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

讲者: Ramez N. Eskander, MD

UPLIFT(ENGOT-ov67/GOG-3048)：upifitamab rilsodotin（一种靶向NaPi2b的dolaflexin 抗体偶联药物）治疗铂类药物耐药卵巢癌的 II 期试验结果

UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate in platinumresistant ovarian cancer

讲者: Debra L. Richardson, MD

Avutometinib + defactinib治疗复发性、低级别浆液性卵巢癌：ENGOT-ov60/GOG-3052/RAMP 201 A部分的亚组分析

Avutometinib plus defactinib in recurrent, low-grade serous ovarian cancer: A subgroup analysis of ENGOT-ov60/GOG-3052/RAMP 201 Part A

讲者: Susana N. Banerjee, MBBS, MA, PhD, FRCP

优化卵巢癌检测的准确性评分：一项多中心、前瞻性、队列研究，评估疑似卵巢癌症状女性诊断准确性（ROCkeTS研究）：绝经后女性的研究结果

Refining ovarian cancer test accuracy scores: A multicentre, prospective, cohort study investigating diagnostic accuracy in women with symptoms of suspected ovarian cancer (The ROCkeTS Study): Results for post-menopausal women

讲者: Sudha Sundar, MBBS, MPhil, MRCOG

APL-1702对宫颈组织学高级别鳞状上皮内病变的长期疗效和安全性：来自一项随机、III期、全球研究的结果

APL-1702 long-term efficacy and safety for cervical histologic, highgrade squamous intraepithelial lesions: Results from a randomized, phase III, global study

讲者: Fei Chen

科学全体会议 Ⅴ：LBA摘要会议2 - 转折点不容错过

Scientific Plenary V: Late Breaking Abstract Session 2 - The Turning Point Don't Be Left Out

专场时间：3月18日 2:30 PM - 3:45 PM

度伐利尤单抗联合卡铂/紫杉醇，序贯度伐利尤单抗±奥拉帕利作为子宫内膜癌的一线治疗（DUO-E/GOG3041/ENGOT-EN10）：根据错配修复状态评估的客观缓解率和缓解持续时间

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status

讲者: Hye Sook Chon, MD

一项在转移性和复发性子宫内膜癌患者中比较 rucaparib 和安慰剂维持治疗的 II 期、随机、双盲研究

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

讲者: Bradley R. Corr, MD

GOG-0258研究的辅助分析：采用改良 ProMisE 算法按分子分类分析的患者总生存期

Overall survival in patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: Ancillary analysis of GOG-0258

讲者: Aine E. Clements, MD

DUO-O/ENGOT-ov46/GOG-3025的更新结果：度伐利尤单抗+紫杉醇/卡铂+贝伐珠单抗，序贯度伐利尤单抗+贝伐珠单抗+奥拉帕尼维持治疗新诊断的非BRCA1/BRCA2突变的晚期卵巢癌患者

Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance in patients with newly-diagnosed, advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-ov46/GOG-3025

讲者: Philipp Harter, MD, PhD

III期 ENGOT-En9/LEAP-001研究：仑伐替尼+帕博利珠单抗对比仑伐替尼+化疗作为晚期或复发性子宫内膜癌一线治疗的初步结果

Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study

讲者: Christian Marth, MD, PhD

在携带 TP53 Y220C 突变的晚期卵巢癌患者亚组中进行的 PC14586 PYNNACLE I/II 期研究的 I 期分析

Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation

讲者: Alison Schram, MD

度伐利尤单抗联合卡铂/紫杉醇，序贯度伐利尤单抗±奥拉帕利作为子宫内膜癌的一线治疗（DUO-E/GOG3041/ENGOT-EN10）：根据错配修复状态评估的总生存期和其他次要疗效终点

Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer: Overall survival and additional secondary efficacy endpoints by mismatch repair status in the DUO-E/GOG3041/ENGOTEN10 Trial

讲者: Jean-François Baurain, MD

在铂敏感性复发性卵巢癌患者中使用个体化起始剂量的尼拉帕利维持治疗（NORA试验）：一项随机、双盲、安慰剂对照、III期试验的最终总生存期分析

Niraparib maintenance therapy using an individualized starting dose in patients with platinum-sensitive, recurrent ovarian cancer (NORA Trial): Final overall survival analysis of a randomized, double-blind, placebo-controlled, phase III trial

讲者: 吴小华, MD

参考文献

https://www.sgo.org/events/annual-meeting/

责任编辑：肿瘤资讯-Jina
排版编辑：肿瘤资讯-张薪媛

专题二维码.png